Lidocaine 700 mg Medicated Plaster for Postherpetic Neuralgia: Real-World Data from the German Pain E-Registry

References

• Scholz J , FinnerupNB , AttalNet al. The IASP classification of chronic pain for ICD-11: chronic neuropathic pain. Pain160, 53–59 (2019).
   PubMed Web of Science ®Google Scholar
• Johnson RW , RiceASC. Postherpetic neuralgia. N. Engl. J. Med.371, 1526–1537 (2014).
   PubMed Web of Science ®Google Scholar
• Johnson RW , BouhassiraD , KassianosG , LeplègeA , SchmaderKE , WeinkeT. The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC Med.8, 37 (2010).
   PubMed Web of Science ®Google Scholar
• Curran D , Schmidt-OttR , SchutterU , SimonJ , AnastassopoulouA. Impact of herpes zoster and postherpetic neuralgia on the quality of life of Germans aged 50 or above. BMC Infect. Dis.18, 496 (2018).
   PubMed Web of Science ®Google Scholar
• Weinke T , GloggerA , BertrandI , LukasK. The societal impact of herpes zoster and postherpetic neuralgia on patients, life partners, and children of patients in Germany. Sci World J. article ID 749698 (2014).
   Google Scholar
• Pickering G , GavazziG , GaillatJ , PaccalinM , BlochK , BouhassiraD. Is herpes zoster an additional complication in old age alongside comorbidity and multiple medications? Results of the post hoc analysis of the 12-month longitudinal prospective observational ARIZONA cohort study. BMJ Open6, e009689 (2016).
   PubMedGoogle Scholar
• Thompson RR , KongCL , PorcoT , KimE , EbertCD , AcharyaNR. Herpes zoster and postherpetic neuralgia: changing incidence rates from 1994 to 2018 in the United States. Clin. Infect. Dis. doi:10.1093/cid/ciaa1185 (2020) ( Epub ahead of print).
   Web of Science ®Google Scholar
• Attal N , CruccuG , BaronRet al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur. J. Neurol.17, 1113–e88 (2010).
   PubMed Web of Science ®Google Scholar
• Finnerup NB , AttalN , HaroutounianSet al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol.14, 162–173 (2015).
   PubMed Web of Science ®Google Scholar
• Baron R , AllegriM , Correa-IllanesGet al. The 5% lidocaine-medicated plaster: its inclusion in international treatment guidelines for treating localized neuropathic pain, and clinical evidence supporting its use. Pain Ther.5, 149–169 (2016).
   PubMed Web of Science ®Google Scholar
• Cave A , KurzX , ArlettP. Real-world data for regulatory decision making: challenges and possible solutions for Europe. Clin. Pharm. Ther.106, 36–39 (2019).
   PubMed Web of Science ®Google Scholar
• Bolislis WR , FayM , KühlerTC. Use of real-world data for new drug applications and line extensions. Clin. Ther.42, 926–938 (2020).
   PubMed Web of Science ®Google Scholar
• Rowbotham MC , DaviesPS , VerkempinckCet al. Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia. Pain65, 39–44 (1996).
   PubMed Web of Science ®Google Scholar
• Galer BS , RowbothamMC , PeranderJet al. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain80, 533–538 (1999).
   PubMed Web of Science ®Google Scholar
• Baron R , MayoralV , LeijonG , BinderA , SteigerwaldI , SerpellM. 5% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study. Curr. Med. Res. Opin.25, 1663–1676 (2009).
   PubMed Web of Science ®Google Scholar
• Binder A , BruxelleJ , RogersP , HansG , BöslI , BaronR. Topical 5% lidocaine (lignocaine) medicated plaster treatment for post-herpetic neuralgia. Results of a double-blind, placebo-controlled, multinational efficacy and safety trial. Clin. Drug Investig.29, 393–408 (2009).
   PubMed Web of Science ®Google Scholar
• Rehm S , BinderA , BaronR. Post-herpetic neuralgia: 5% lidocaine medicated plaster, pregabalin, or a combination of both? A randomized, open, clinical effectiveness study. Curr. Med. Res. Opin.26, 1607–1619 (2010).
   PubMed Web of Science ®Google Scholar
• Hans G , SabatowskiR , BinderAet al. Efficacy and tolerability of a 5% lidocaine medicated plaster for the topical treatment of post-herpetic neuralgia: results of a long-term study. Curr. Med. Res. Opin.25, 1295–1305 (2009).
   PubMed Web of Science ®Google Scholar
• Sabatowski R , HansG , TackenI , KapanadzeS , BuchheisterB , BaronR. Safety and efficacy outcomes of long-term treatment up to 4 years with 5% lidocaine medicated plaster in patients with post-herpetic neuralgia. Curr. Med. Res. Opin.28, 1337–1346 (2012).
   PubMed Web of Science ®Google Scholar
• Sabatowski R , BöslI , KönigS , BuchheisterB , MeierT , BaronR. Treatment of postherpetic neuralgia with 5% lidocaine medicated plaster in elderly patients – subgroup analyses from three European clinical trials. Curr. Med. Res. Opin.33, 595–603 (2017).
   PubMed Web of Science ®Google Scholar
• Binder A , RogersP , HansG , BaronR. Impact of topical 5% lidocaine-medicated plasters on sleep and quality of life in patients with postherpetic neuralgia. Pain Manag.6, 229–239 (2016).
   PubMed Web of Science ®Google Scholar
• Campbell BJ , RowbothamM , DaviesPS , JacobPIII , BenowitzNL. Systemic absorption of topical lidocaine in normal volunteers, patients with post-herpetic neuralgia, and patients with acute herpes zoster. J. Pharm. Sci.91, 1343–1350 (2002).
   PubMed Web of Science ®Google Scholar
• Navez ML , MonellaC , BöslI , SommerD , DelormeC. 5% lidocaine medicated plaster for the treatment of postherpetic neuralgia: a review of the clinical safety and tolerability. Pain Ther.4, 1–15 (2015).
   PubMed Web of Science ®Google Scholar
• Schlereth T et al. Diagnosis and noninterventional treatment of neuropathic pain, S2k guideline (in German). In: Guidelines for Diagnosis and Treatment in Neurology.German Society of Neurology (2019). https://www.awmf.org/uploads/tx_szleitlinien/030-114l_S2k_Diagnose-nicht-interventionelle-Therapie-neuropathischer-Schmerzen_2020-04_1.pdf
   Google Scholar
• German Pain Society . Manual for the German Pain Questionnaire (in German). https://www.schmerzgesellschaft.de/fileadmin/pdf/DSF_Handbuch_2020.pdf
   Google Scholar
• von Korff M , OrmelJ , KeefeFJ , DworkinSF. Grading the severity of chronic pain. Pain50, 133–149 (1992).
   PubMed Web of Science ®Google Scholar
• Schmitt N , GerbershagenHU. The Mainz Staging System (MPSS) for chronic pain. Pain41(Suppl. 5), S484 (1990).
   Google Scholar
• Tait RC , ChibnallJT , KrauseS. The pain disability index: psychometric properties. Pain40, 171–182 (1990).
   PubMed Web of Science ®Google Scholar
• Ware J Jr , KosinskiM , KellerSD. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med. Care34, 220–233 (1996).
   PubMed Web of Science ®Google Scholar
• Gandek B , WareJE , AaronsonNKet al. Cross-validation of item selection and scoring for the SF-12 health survey in nine countries: results from the IQOLA project. J. Clin. Epidemiol.51, 1171–1178 (1998).
   PubMed Web of Science ®Google Scholar
• Guy W . ECDEU Assessment Manual for Psychopharmacology (DHEW Publication no. ADM 76–338).US Government Printing Office, DC, USA (1976).
   Google Scholar
• Lin PL , FanSZ , HuangCHet al. Analgesic effect of lidocaine patch 5% in the treatment of acute herpes zoster: a double-blind and vehicle-controlled study. Reg. Anesth. Pain Med.33, 320–325 (2008).
   PubMed Web of Science ®Google Scholar
• Garnock-Jones KP , KeatingGM. Lidocaine 5% medicated plaster. A review of its use in postherpetic neuralgia. Drugs69, 2149–2165 (2009).
   PubMed Web of Science ®Google Scholar
• de León-Casasola OA , MayoralV. The topical 5% lidocaine medicated plaster in localized neuropathic pain: a reappraisal of the clinical evidence. J. Pain Res.9, 67–79 (2016).
   PubMed Web of Science ®Google Scholar
• Sheets PL , JareckiBW , CumminsTR. Lidocaine reduces the transition to slow inactivation in NaV1.7 voltage-gated sodium channels. Br. J. Pharmacol.164, 719–730 (2011).
   PubMed Web of Science ®Google Scholar
• Wolff RF , BalaMM , WestwoodM , KesselsAG , KleijnenJ. 5% lidocaine-medicated plaster vs other relevant interventions and placebo for post-herpetic neuralgia (PHN): a systematic review. Acta Neurol. Scand.123, 295–309 (2011).
   PubMed Web of Science ®Google Scholar
• Buksnys T , ArmstrongN , WorthyGet al. Systematic review and network meta-analysis of the efficacy and safety of lidocaine 700 mg medicated plaster vs. pregabalin. Curr. Med. Res. Opin.36, 101–115 (2020).
   PubMed Web of Science ®Google Scholar
• Katz P , PegoraroV , LiedgensH. Characteristics, resource utilization and safety profile of patients prescribed with neuropathic pain treatments: a real-world evidence study on general practices in Europe - the role of the lidocaine 5% medicated plaster. Curr. Med. Res. Opin.33(8), 1481–1489 (2017).
   PubMed Web of Science ®Google Scholar
• Pickering G , LeplegeA. Herpes zoster pain, postherpetic neuralgia, and quality of life in the elderly. Pain Pract.11, 397–402 (2011).
   PubMed Web of Science ®Google Scholar
• Überall MA , Müller-SchwefeGHH. Patient perceptions associated with the 5% lidocaine medicated plaster in daily practice. Curr. Med. Res. Opin.28, 901–909 (2012).
   PubMed Web of Science ®Google Scholar